Neurofibromatosis type 1 and hypertension in pediatrics: Case report;Neurofibromatosi 1 ed ipertensione arteriosa in età pediatrica: Caso clinico

Minerva Pediatrica

Volumn 63, Issue 4, 2011, Pages 335-339

  Demarchi, I ^a   Genoni, G ^a   Prodam, F ^a   Petri, A ^a   Busti, A ^a   Cortese, L ^a   Negro, M ^a   Bellone, S ^a   Acucella, G ^a   Bona, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Hypertension; Neurofibromatoses; Therapeutics

Indexed keywords

ALDOSTERONE; METADRENALIN; POTASSIUM; RENIN;

ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CAFE AU LAIT SPOT; CASE REPORT; CHILD; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; MAGNETIC RESONANCE ANGIOGRAPHY; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE GLIOMA; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; SCHOOL CHILD; SKIN; VASCULAR DISEASE;

ANTIHYPERTENSIVE AGENTS; AXILLA; BLOOD PRESSURE MONITORING, AMBULATORY; BRAIN NEOPLASMS; CAFE-AU-LAIT SPOTS; CHILD; DIAGNOSIS, DIFFERENTIAL; EYE DISEASES; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; HYPERTENSION; NEUROFIBROMA; NEUROFIBROMATOSIS 1; OPTIC NERVE GLIOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 80755142822     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hirsch NP, Murphhy A, Radcliffe JJ. Neurofibromatosis: clinical presentations and anaesthetic implicatios. Br J Anaesth 2001;86:555-64. (Pubitemid 32273124)
2. Korf BR. Diagnosis and management of neurofibromatosis type 1. Curr Neurol Neurosci Rep 2001;1:162-7.
3. rd edition. Baltimore, MD: Johns Hopkins University Press; 1999. p. 29-86.
4. Viskochil D. Neurofibromatosis 1. Am J Med Genet 1999;89:V-VIII.
5. Lama G, Grassia C, Avino G, Esposito Salsano M, Calabrese E et al. Neurofibromatosis type 1 in children: 10 years of experience. Riv Ital Pediatr 1998;24:99-107. (Pubitemid 128752261)
6. Reynolds RM, Browning GGP, Nawroz I, Campbell IW. Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet 2003;361:1552-4. (Pubitemid 36566351)
7. Scheithauer BW, Woodruff JM, Erlandson RA. Tumors of the peripheral nervous system. Washington, DC: Armed Forces Instituteof Pathology; 1999.
8. Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999;89:38-44. (Pubitemid 30033175)
9. Korf BR. Clinical features and pathobiology of neurofibromatosis 1. J Child Neurol. 2002;17:573-7; discussion 602-604, 646-651.
10. Friedman JM. Neurofibromatosis 1:clinical manifestations and diagnostic criteria. J Child Neurol 2002;17:548-54; discussion 571-2; 646-51.
11. Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG. Decreased bone mineral density in neurofibromatosis type 1.results from a pediatric cohort. J Pediatr Orthop 2007;27:472-5. (Pubitemid 46868318)
12. Virdis R, Balestrazzi P, Zampolli M, Donadio A, Street M, Lorenzetti E. Hypertension in children with neurofibromatosis. J Hum Hypertens 1994;8:395-7. (Pubitemid 24155927)
13. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE et al. Cardiovascular disease in neurofibromatosis 1:report of the NF1 cardiovascular task force. Genet Med 2002;4:105-11. (Pubitemid 44698568)
14. Koch CA, Vortmeyer AO, Huang SC, Alesci S, Zhuang Z, Pacak K. Genetic aspects of phaeochromocytoma. Endocr Regul 2001;35:43-52.
15. Cacciari E, Milani S, Balsamo A, Directive Councils of SIEDP/ISPED. J Endocrinol Invest 2006;29:581-93.
16. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 2004;114;555-76.
17. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism:an endocrine society clinical practice guideline. JCEM 2008;3266-81.
18. Oderich GS, Sullivan TM, Bower TC, Gloviczki P, Miller DV, Babovic-Vuksanovic D et al. Vascular abnormalities in patients with neurofibromatosis syndrome type I:clinical spectrum, management, and results. J Vasc Surg 2007;46:475-84.
19. Lama G, Graziano L, Calabrese E, Grassia C, Rimbaldi PF, Cioce F et al. Blood pressure and cardiovascular involvement in children with neurofibromatosis tye 1. Pediatr Nephrol 2004;19:413-8. (Pubitemid 38477405)
20. Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F. Pheochromocytoma:an update on genetics and management. Endocr Relat Cancer 2007;144:935-56.
21. Kurien A, Jhon PR, Milford DV. Hypertension secondary to progressive vascular neurofibromatosis. Arch Dis Child 1997;76:454-5. (Pubitemid 27261866)
22. Norton KK, Xu J, Gutmann DH. Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 1995;2:13-21.
23. Huppman JL, Gathon V, Bowers VD:Neurofibromatosis and arterial aneurysm. Am Surg 1996;62:311-4.
24. Teitelbaum GP, Hurvitz RJ, Esrig BC. Hemothorax in type 1 neurofibromatosis. Ann Thorac Surg 1998;66:569-71.
25. Green JF Jr, Fitzwater JE, Burgess J. Arterial lesions associated with neurofibromatosis. Am J Clin Pathol 1992;22:66-106.
26. Lasater EA, Li F, Bessler WK, Estes ML, Vemula S, Hingtgen CM et al. Genetic and cellular evidence of vascular inflammation in neurofibromin- deficient mice and humans. J Clin Invest 2010 [Epub ahead of print].